T1	p 246 266	patients with asthma
T2	p 691 707	adult asthmatics
T3	p 718 736	Sixty-six subjects
T4	i 6 16	Salmeterol
T5	i 22 44	fluticasone propionate
T6	i 52 74	fluticasone propionate
T7	i 80 91	montelukast
T8	i 504 514	salmeterol
T9	i 520 568	fluticasone propionate ( FP ) ( Seretide ; SFC )
T10	i 573 575	FP
T11	i 581 601	montelukast ( FP/M )
T12	i 756 759	SFC
T13	i 763 767	FP/M
T14	i 1295 1298	SFC
T15	i 1379 1383	FP/M
T16	i 1386 1390	FP/M
T17	i 1469 1472	SFC
T18	i 1660 1663	SFC
T19	o 153 172	airway inflammation
T20	o 605 672	sputum inflammatory markers , airway responsiveness , lung function
T21	o 679 687	symptoms
T22	o 807 914	changes in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum
T23	o 950 1065	change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function
T24	o 1129 1148	sputum inflammatory
T25	o 1203 1221	sputum eosinophils
T26	o 1263 1284	airway responsiveness
T27	o 1340 1373	symptom control and lung function
T28	o 1434 1463	sputum cysteinyl leukotrienes
T29	o 1575 1607	eosinophilic airway inflammation